The Goldman Sachs Group lowers Intra-Cellular Therapies (NASDAQ:ITCI) price target to $74.00
Intracellular Therapies (NASDAQ:ITCI – Request a Free Report) The price target was cut by Goldman Sachs Group from $77.00 to $74.00 in a research note published on Thursday, Benzinga reports.…
